A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

Name: A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
Published: 2026
License: Public Domain

Nader Sanai · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

adc

glioblastoma (gbm), brain metastasases, adc, antibody drug conjugate, interventional, early_phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

Related documents